STOCKUPSIDE.IO
Analyst Price Target Intelligence
← Full Rankings
← Back to rankings
Ranked #2063 by analyst upside · 2026-06-27
RYTM
Rhythm Pharmaceuticals, Inc.
Healthcare · Market Cap $8B · P/E 0x
ANALYST PRICE TARGET
+27.0%
implied upside to consensus target
Current Price $109.84
Consensus Target $139.47
Bull Target $159.0
Bear Target $105.0
Analysts Covering 15
ANALYST CONSENSUS — BUY
Strong Buy
4
Buy
10
Hold
1
Sell
0
52-Week Low $61.0
52-Week High $122.2
YTD Return +4.6%
FUNDAMENTALS
Market Cap $8B
P/E Ratio (TTM) N/A
Forward P/E -148.2x
EPS (TTM) $-3.13
PEG Ratio N/A
Dividend Yield N/A
Revenue (TTM) $217M
Profit Margin -93.3%
52-WEEK RANGE
52-Week Low $61.0
52-Week High $122.2
Current Price $109.84
Bear Target $105.0
Bull Target $159.0
● Now $109.84 ● Target $139.47
TRADING DATA
Avg Volume 795K
YTD Return +4.6%
Analyst Count 15
Consensus Buy
Upside to Target +27.0%
Last Updated 2026-06-27

ANALYST SUMMARY

Rhythm Pharmaceuticals, Inc. (RYTM) is currently trading at $109.84 with a Wall Street consensus price target of $139.47, implying potential upside of 27.0% over the next 12 months. 15 analysts currently cover RYTM, with a consensus rating of Buy — 93% of analysts rate the stock a Buy or Strong Buy. The most bullish analyst has a price target of $159.0, while the most cautious has a target of $105.0.

RYTM operates in the Healthcare sector with a market capitalisation of $8B. The stock is up 4.6% year-to-date and is currently trading near the upper end of its 52-week range of $61.0 – $122.2.

SIMILAR STOCKS

Other Healthcare stocks with comparable size and valuation.

RECENT ANALYST CALLS

Upgrade/downgrade history for RYTM, with each firm's 90-day track record across all stocks we track. See full firm rankings →

Canaccord Genuity — Reiterated
Buy → Buy 2026-06-16 Building track record
Wells Fargo — Reiterated
Overweight → Overweight 2026-06-15 Building track record
Canaccord Genuity — Reiterated
Buy → Buy 2026-05-07 Building track record
RBC Capital — Reiterated
Outperform → Outperform 2026-05-06 Building track record
Wells Fargo — Reiterated
Overweight → Overweight 2026-05-06 Building track record
HC Wainwright & Co. — Reiterated
Buy → Buy 2026-03-23 31% win rate (48 calls)
Citigroup — Reiterated
Buy → Buy 2026-03-20 Building track record
B of A Securities — Reiterated
Buy → Buy 2026-03-20 Building track record
HISTORICAL SNAPSHOT

Point-in-time data from StockUpside's daily snapshots. Tracks price, analyst target, upside %, consensus, and analyst count.

Loading…
ANALYST CONVICTION SCORE
out of 100
Coverage depth
0/30
Consensus clarity
0/30
Vote unanimity
0/25
Rating stability
0/15

Measures analyst agreement, not fundamental quality. A high score means analysts broadly agree on this call — not that the stock will go up.

See 4,000+ stocks ranked by analyst upside

StockUpside.io tracks analyst consensus price targets across thousands of US-listed stocks, updated every day. The full ranked list is available with a Pro subscription.

View Full Rankings →